首頁 > 市場調查報告書 > 製藥

再生醫學細胞療法

市場調查報告書

商品編碼

1736602

同種異體幹細胞移植市場：依來源、應用、最終用戶、細胞類型和地區分類

Allogeneic Stem Cell Transplantation Market, By Source, By Application, By End User, By Cell Type, By Geography

出版日期: 2025年04月25日 | 出版商:

Coherent Market Insights | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

異體幹細胞移植市場規模預計在 2025 年為 45.3 億美元，預計到 2032 年將達到 76.6 億美元，2025 年至 2032 年的複合年成長率為 7.8%。

報告範圍		報告詳細資訊
基準年	2024	2025年的市場規模	45.3億美元
效能數據	從2020年到2024年	預測期	2025年至2032年
預測期：2025-2032年複合年成長率：	7.80%	2032年價值預測	76.6億美元

圖：2025年異體幹細胞移植市場佔有率（%），依地區分類

異體幹細胞移植是一種將幹細胞從捐贈者轉移到接受者的醫療程序。這些幹細胞可以從多種來源獲取，包括骨髓、周邊血和臍帶血。移植的目的是透過用健康細胞取代受損或患病的細胞來恢復接受者器官和組織的功能。異體幹細胞移植用於治療多種疾病，包括癌症、遺傳性疾病和某些免疫系統疾病。

全球異體幹細胞移植市場正經歷顯著成長，原因是此類治療方法可治癒的疾病日益增多。此外，移植技術的進步和新療法的市場發展也進一步促進了市場的成長。市場的主要企業包括 Celgene Corporation、Mesoblast Ltd.、Pluristem Therapeutics Inc. 和工業株式會社。

市場動態：

可以透過影響市場的促進因素、限制因素和機會來分析同種異體幹細胞移植市場的市場動態。

促進因素：白血病、淋巴瘤、多發性骨髓瘤等需要幹細胞移植的疾病的發生率不斷上升，是市場的主要驅動力。此外，老年人口的成長、移植技術的進步以及幹細胞庫數量的增加也推動了市場的成長。
限制因素：幹細胞移植的高成本以及相關併發症（例如移植物抗宿主疾病）的風險是市場的主要限制因素。此外，某些地區對異基因幹細胞移植潛在益處的認知度較低，也阻礙了市場的成長。
機會：創新治療方法的開發和異體幹細胞移植新應用的探索可能帶來巨大的成長機會。此外，加大研發投入以及主要企業與研究機構之間的合作，也可望推動市場成長。

本研究的主要特點

本報告對全球異體幹細胞移植市場進行了詳細分析，包括預測期為 2025 年至 2032 年的市場規模和複合年成長率（假設 2024 年為基準年）。
它強調了各個細分市場中的潛在收益成長機會，並說明了該市場的引人注目的投資提案矩陣。
它提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的重要見解。
全球異體幹細胞移植市場的關鍵參與者包括 Celgene Corporation、Mesoblast Ltd.、Pluristem Therapeutics Inc.、工業等，根據公司亮點、產品系列、關鍵亮點、財務績效、策略等進行分析。
本報告將為負責人和經營團隊提供有價值的訊息，使他們能夠就未來的產品發布、市場擴張和行銷策略做出明智的決策。
它迎合了行業中的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和財務分析師，並為決策提供見解。
相關人員可以從全球異體幹細胞移植市場分析中使用的各種策略矩陣中受益，從而提高決策流程的便利性。

Celgene Corporation
Mesoblast Ltd.
Pluristem Therapeutics Inc.
MEDIPOST Co., Ltd.
Osiris Therapeutics, Inc.
Cynata Therapeutics Limited
Takeda Pharmaceutical Company Limited
Astellas Pharma Inc.
Cellular Biomedicine Group, Inc.
Biosolution Co., Ltd.
StemCell Technologies Inc.
Caladrius Biosciences, Inc.
TiGenix NV
ViaCord
Vericel Corporation
Regen Biopharma Inc.
Gamida Cell Ltd.
Histogenics Corporation
BrainStorm Cell Therapeutics Inc.
Lineage Cell Therapeutics, Inc.

第 11 章章節

調查方法
關於出版商

簡介目錄

Product Code: CMI6407

Allogeneic Stem Cell Transplantation Market is estimated to be valued at USD 4.53 Bn in 2025 and is expected to reach USD 7.66 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 7.8% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 4.53 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	7.80%	2032 Value Projection:	USD 7.66 Bn

Figure. Allogeneic Stem Cell Transplantation Market Share (%), By Region 2025

Allogeneic Stem Cell Transplantation Market - IMG1

Allogeneic stem cell transplantation is a medical procedure that involves the transfer of stem cells from a donor to a recipient. These stem cells can be obtained from various sources such as bone marrow, peripheral blood, or umbilical cord blood. The aim of this procedure is to replace damaged or diseased cells with healthy ones, thereby restoring the function of the recipient's organs or tissues. Allogeneic stem cell transplantation has been used for the treatment of a wide range of conditions including cancers, genetic disorders, and certain immune system disorders.

The global allogeneic stem cell transplantation market is witnessing significant growth due to the increasing prevalence of diseases that can be treated through this procedure. Moreover, advancements in transplantation techniques, as well as the development of new therapeutic approaches, are further contributing to the market growth. The market is characterized by the presence of several key players including Celgene Corporation, Mesoblast Ltd., Pluristem Therapeutics Inc., and Takeda Pharmaceutical Company Limited, among others.

Market Dynamics:

The market dynamics of the allogeneic stem cell transplantation market can be analyzed through the drivers, restraints, and opportunities that shape the market.

Drivers: The increasing incidence of diseases that require stem cell transplantation, such as leukemia, lymphoma, and multiple myeloma, is a major driver for the market. Additionally, the growing geriatric population, advancements in transplantation techniques, and the rise in stem cell banking facilities are also fueling the market growth.
Restraints: The high costs associated with stem cell transplantation procedures and the risk of complications, such as graft-versus-host disease, act as significant restraints for the market. Moreover, the lack of awareness about the potential benefits of allogeneic stem cell transplantation in certain regions hinders the market growth.
Opportunities: The development of innovative therapies and the exploration of new applications for allogeneic stem cell transplantation present significant growth opportunities. Moreover, increasing investments in research and development activities and collaborations between key players and research institutions can drive the market growth.

Key Features of the Study:

This report provides an in-depth analysis of the global allogeneic stem cell transplantation market, including market size (US$ Bn) and Compound Annual Growth Rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
It highlights potential revenue growth opportunities across different market segments and explains attractive investment proposition matrices for this market
The study offers key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
Key players in the global allogeneic stem cell transplantation market include Celgene Corporation, Mesoblast Ltd., Pluristem Therapeutics Inc., and Takeda Pharmaceutical Company Limited, and they are profiled based on company highlights, product portfolios, key highlights, financial performance, and strategies
The report provides valuable information to marketers and management authorities, enabling them to make informed decisions regarding future product launches, market expansion, and marketing tactics
It caters to various stakeholders in the industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts, providing them with insights for decision-making
Stakeholders can benefit from the various strategy matrices used in analyzing the global allogeneic stem cell transplantation market, enhancing ease in decision-making processes

Allogeneic Stem Cell Transplantation Market Segmentation:

By Source
- Bone Marrow
- Peripheral Blood
- Umbilical Cord Blood
- Adipose Tissue
- Dental Pulp
- Others
By Application
- Cancer
- Autoimmune Diseases
- Blood Disorders
- Cardiac Disorders
- Neurological Disorders
- Diabetes
- Others
By End User
- Hospitals
- Research Institutes
- Specialty Clinics
- Others
By Cell Type
- Allogeneic MSCs
- Allogeneic HSCs
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Celgene Corporation
- Mesoblast Ltd.
- Pluristem Therapeutics Inc.
- MEDIPOST Co., Ltd.
- Osiris Therapeutics, Inc.
- Cynata Therapeutics Limited
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc.
- Cellular Biomedicine Group, Inc.
- Biosolution Co., Ltd.
- StemCell Technologies Inc.
- Caladrius Biosciences, Inc.
- TiGenix N.V.
- ViaCord
- Vericel Corporation
- Regen Biopharma Inc.
- Gamida Cell Ltd.
- Histogenics Corporation
- BrainStorm Cell Therapeutics Inc.
- Lineage Cell Therapeutics, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Allogeneic Stem Cell Transplantation Market , By Source
- Allogeneic Stem Cell Transplantation Market , By Cell Type
- Allogeneic Stem Cell Transplantation Market , By Application
- Allogeneic Stem Cell Transplantation Market , By End User
- Allogeneic Stem Cell Transplantation Market , By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
  - Rising incidence of chronic diseases
- Restraints
  - High costs associated with cell therapies
- Opportunities
  - Increasing use of allogeneic MSCs
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Allogeneic Stem Cell Transplantation Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Allogeneic Stem Cell Transplantation Market, By Source, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Bone Marrow
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Peripheral Blood
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Umbilical Cord Blood
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Adipose Tissue
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Dental Pulp
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Allogeneic Stem Cell Transplantation Market, By Cell Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Allogeneic MSCs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Allogeneic HSCs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

7. Allogeneic Stem Cell Transplantation Market, By Application, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Autoimmune Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Blood Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Cardiac Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

8. Allogeneic Stem Cell Transplantation Market, By End User, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

9. Allogeneic Stem Cell Transplantation Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, By Region, 2023and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cell Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - U.S.
  - Canada
Europe
Asia Pacific
Latin America
Middle East
Africa

10. Competitive Landscape

Celgene Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Mesoblast Ltd.
Pluristem Therapeutics Inc.
MEDIPOST Co., Ltd.
Osiris Therapeutics, Inc.
Cynata Therapeutics Limited
Takeda Pharmaceutical Company Limited
Astellas Pharma Inc.
Cellular Biomedicine Group, Inc.
Biosolution Co., Ltd.
StemCell Technologies Inc.
Caladrius Biosciences, Inc.
TiGenix N.V.
ViaCord
Vericel Corporation
Regen Biopharma Inc.
Gamida Cell Ltd.
Histogenics Corporation
BrainStorm Cell Therapeutics Inc.
Lineage Cell Therapeutics, Inc.
Analyst Views